stoxline Quote Chart Rank Option Currency Glossary
  
Vanda Pharmaceuticals Inc. (VNDA)
6.35  0.11 (1.76%)    06-17 16:00
Open: 6.3
High: 6.63
Volume: 1,113,925
  
Pre. Close: 6.24
Low: 6.101
Market Cap: 370(M)
Technical analysis
2024-06-17 5:27:17 PM
Short term     
Mid term     
Targets 6-month :  7.88 1-year :  9.2
Resists First :  6.75 Second :  7.88
Pivot price 5.63
Supports First :  5.58 Second :  4.86
MAs MA(5) :  6.19 MA(20) :  5.51
MA(100) :  4.58 MA(250) :  4.71
MACD MACD :  0.3 Signal :  0.2
%K %D K(14,3) :  79.5 D(3) :  75.1
RSI RSI(14): 65.1
52-week High :  6.76 Low :  3.29
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ VNDA ] has closed below upper band by 19.7%. Bollinger Bands are 115.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.64 - 6.67 6.67 - 6.7
Low: 6.03 - 6.06 6.06 - 6.09
Close: 6.3 - 6.35 6.35 - 6.4
Company Description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Headline News

Fri, 14 Jun 2024
GSA Capital Partners LLP Boosts Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Fri, 14 Jun 2024
GSA Capital Partners LLP Boosts Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Defense World

Thu, 13 Jun 2024
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak - StockTitan

Thu, 13 Jun 2024
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak - PR Newswire

Thu, 13 Jun 2024
Vanda Pharmaceuticals stock gains as Future Pak raises offer to $8.50-$9 a share - Seeking Alpha

Fri, 07 Jun 2024
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 58 (M)
Shares Float 52 (M)
Held by Insiders 3.1 (%)
Held by Institutions 86.6 (%)
Shares Short 2,800 (K)
Shares Short P.Month 2,070 (K)
Stock Financials
EPS -0.1
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.35
Profit Margin -2.8 %
Operating Margin -19.5 %
Return on Assets (ttm) -2.5 %
Return on Equity (ttm) -1 %
Qtrly Rev. Growth -24.2 %
Gross Profit (p.s.) 0
Sales Per Share 3.05
EBITDA (p.s.) -0.36
Qtrly Earnings Growth 0 %
Operating Cash Flow -11 (M)
Levered Free Cash Flow -115 (M)
Stock Valuations
PE Ratio -70.56
PEG Ratio -2.9
Price to Book value 0.67
Price to Sales 2.08
Price to Cash Flow -32.34
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android